WO2011065800A3 - 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 - Google Patents

피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 Download PDF

Info

Publication number
WO2011065800A3
WO2011065800A3 PCT/KR2010/008522 KR2010008522W WO2011065800A3 WO 2011065800 A3 WO2011065800 A3 WO 2011065800A3 KR 2010008522 W KR2010008522 W KR 2010008522W WO 2011065800 A3 WO2011065800 A3 WO 2011065800A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
same
composition containing
bone
pyrimidine derivative
Prior art date
Application number
PCT/KR2010/008522
Other languages
English (en)
French (fr)
Other versions
WO2011065800A2 (ko
Inventor
김세원
김정근
김세년
강대필
황해준
김영삼
Original Assignee
주식회사 오스코텍
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 오스코텍 filed Critical 주식회사 오스코텍
Publication of WO2011065800A2 publication Critical patent/WO2011065800A2/ko
Publication of WO2011065800A3 publication Critical patent/WO2011065800A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명의 피리미딘 유도체 화합물은, 조골세포의 분화를 촉진시켜 골밀도를 증가시키므로 골다공증과 같은 대사성 골 질환의 예방 및 치료뿐 아니라 성장기의 골 형성에도 유용하게 활용될 수 있다. 또한 본 발명의 약학적 조성물은 신성골이양증, 골연화증, 파제트병, 골형성 부전증 등 여러 가지 대사성 골질환의 치료제로 쓰일 수 있으며, 골절의 치료, 암의 골전이를 억제하는 치료제로도 이용될 수 있다.
PCT/KR2010/008522 2009-11-30 2010-11-30 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 WO2011065800A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090117195 2009-11-30
KR10-2009-0117195 2009-11-30

Publications (2)

Publication Number Publication Date
WO2011065800A2 WO2011065800A2 (ko) 2011-06-03
WO2011065800A3 true WO2011065800A3 (ko) 2011-10-27

Family

ID=44067142

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/008522 WO2011065800A2 (ko) 2009-11-30 2010-11-30 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물

Country Status (1)

Country Link
WO (1) WO2011065800A2 (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290499B2 (en) 2010-05-19 2016-03-22 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
AU2016244228B2 (en) * 2011-04-22 2019-02-21 Signal Pharmaceuticals, Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
MX351754B (es) 2011-04-22 2017-10-27 Signal Pharm Llc Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y metodos de tratamiento con las mismas.
RU2631655C2 (ru) 2011-10-03 2017-09-26 Зэ Юниверсити Оф Норд Каролина Эт Чапель Хилл Пирролопиримидиновые соединения для лечения злокачественной опухоли
MX2014013632A (es) * 2012-05-22 2015-02-05 Univ North Carolina Compuestos de pirimidina para el tratamiento de cancer.
EP2909211A4 (en) 2012-10-17 2016-06-22 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
EA028052B1 (ru) * 2012-11-08 2017-10-31 Бристол-Майерс Сквибб Компани АЛКИЛАМИДЗАМЕЩЁННЫЕ ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ МОДУЛЯЦИИ IL-12, IL-23 И/ИЛИ IFNα
EP2925752A4 (en) 2012-11-27 2016-06-01 Univ North Carolina PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
US20150291609A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrimidine compounds
US9796685B2 (en) 2014-12-16 2017-10-24 Signal Pharmaceuticals, Llc Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamide
WO2016100308A1 (en) 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-jun n-terminal kinase in skin
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
AU2016297784B2 (en) 2015-07-24 2020-12-24 Celgene Corporation Methods of synthesis of (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
US10961242B2 (en) 2017-05-17 2021-03-30 Legochem Biosciences, Inc. Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
KR101798840B1 (ko) * 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
KR102006547B1 (ko) * 2017-11-16 2019-08-01 서울대학교산학협력단 벤즈아미드 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 염증질환의 치료 또는 예방용 약학적 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039101A1 (en) * 1998-12-24 2000-07-06 Astrazeneca Ab Pyrimidine compounds
WO2001029042A1 (en) * 1999-10-21 2001-04-26 F. Hoffmann-La Roche Ag Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
US6432963B1 (en) * 1997-12-15 2002-08-13 Yamanouchi Pharmaceutical Co., Ltd. Pyrimidine-5-carboxamide derivatives
WO2005042519A1 (en) * 2003-10-31 2005-05-12 Warner-Lambert Company Llc Pyrimidines as inhibitors of phosphoinositide -3-kinases (pi3k)
WO2006038112A1 (en) * 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
US7449456B2 (en) * 2002-06-28 2008-11-11 Astellas Pharma, Inc. Diaminopyrimidinecarboxamide derivative

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432963B1 (en) * 1997-12-15 2002-08-13 Yamanouchi Pharmaceutical Co., Ltd. Pyrimidine-5-carboxamide derivatives
WO2000039101A1 (en) * 1998-12-24 2000-07-06 Astrazeneca Ab Pyrimidine compounds
WO2001029042A1 (en) * 1999-10-21 2001-04-26 F. Hoffmann-La Roche Ag Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
US7449456B2 (en) * 2002-06-28 2008-11-11 Astellas Pharma, Inc. Diaminopyrimidinecarboxamide derivative
WO2005042519A1 (en) * 2003-10-31 2005-05-12 Warner-Lambert Company Llc Pyrimidines as inhibitors of phosphoinositide -3-kinases (pi3k)
WO2006038112A1 (en) * 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis

Also Published As

Publication number Publication date
WO2011065800A2 (ko) 2011-06-03

Similar Documents

Publication Publication Date Title
WO2011065800A3 (ko) 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
WO2013009701A3 (en) Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
MX2008016134A (es) Derivados de fenol para el tratamiento de enfermedades respiratorias.
MXPA05010712A (es) Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
WO2008100384A3 (en) Activin-actriia antagonists and uses for promoting bone growth in cancer patients
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
WO2005124342A3 (en) Methods and means for treatment of osteoarthritis
EP2985281A3 (en) Isoindoline compounds for use in the treatment of cancer
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
EP2966065A3 (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
MY150059A (en) Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
MX2009012271A (es) Compuestos antagonistas de acido ribonucleico para la modulacion de her3.
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
WO2010071826A3 (en) Methods for treating osteoclast-related disease, compounds and compositions thereof
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2007055885A3 (en) Pharmaceutical gallium compositions and methods
TNSN07419A1 (en) Methods for treating drug resistant cancer
WO2013040227A3 (en) Therapeutic compounds
UA101393C2 (ru) КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ТРИАЗОЛА ДЛЯ ЛЕЧЕНИЯ β-АМИЛОИДОЗОВ И СИНУКЛЕИНОПАТИЙ
WO2011023367A3 (en) Bisphosphonate-prodrugs
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
EP2131849A4 (en) COMPOSITIONS AND METHODS OF DISTRIBUTING AGENTS AGAINST CANCER
WO2010036567A3 (en) Harmine compounds for promoting bone growth

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10833612

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10833612

Country of ref document: EP

Kind code of ref document: A2